ArticleBMC infectious diseases2026
Effective treatment of scabetic nodules with thalidomide: a 5-year retrospective case series.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundScabetic nodules are a cutaneous hypersensitivity reaction to scabies mites and their byproducts, often accompanied by persistent pruritus. These nodules remain a therapeutic challenge due to the lack of effective treatments.
objectiveWe sought to assess the effectiveness and tolerance of thalidomide for genital scabetic nodules.
methodsWe performed a retrospective evaluation of thalidomide treatment (50-200 mg/day for 2-3 consecutive weeks) in 38 male patients with genital nodular scabies who had previously been infested with scabies mites and were left with persistent pruritic nodules on the genitals.
resultsA total of 38 male patients (age range: 18-40 years; mean age: 28.2 ± 5.79 years) with post scabetic nodules were included. Some of them had been refractory to other forms of therapy. Of the 38 patients, 28 patients (73.7%) showed nodule resolution after 2 weeks of treatment. A significant reduction in the number of nodules was observed at the end of the three-week treatment period (P < 0.05), and there was no sign of relapsing. Meanwhile, after two weeks of thalidomide treatment, the patient's pruritus symptoms significantly improved, manifested as a significant decrease in VAS (P < 0.05), and after three weeks of treatment, VAS further significantly decreased (P < 0.05). Infrequent adverse events, including rash, mild dizziness, and/or drowsiness, occurred in nine patients and resolved after drug withdrawal.
conclusionThalidomide may be a promising option for treating refractory scabies nodules. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.